文献速递炎症性肠病

抗TNFα暴露婴儿首年疫苗接种安全性:法国全国队列

Safety of first year vaccination in children born to mothers with inflammatory bowel disease and exposed in utero to anti-TNFα agents: a French nationwide population-based cohort.
PubMed 文献 · Aliment Pharmacol Ther · 2019-10-15

基于法国健康保险数据库2013–2014年出生的4741名IBD母亲子女,670名(14.1%)产前暴露于抗TNFα。暴露儿BCG接种率较低(13.1% vs 19.2%)且接种较晚,但88名接种者中73%在6月龄前接种,首年未观察到BCG相关严重不良事件;其他推荐疫苗覆盖率两组均超85%。

要点

  • 产前抗TNFα暴露儿BCG接种率低于未暴露儿,且接种时间更晚。
  • 88名暴露儿接种BCG,73%在6月龄前接种,首年无BCG相关严重不良事件。
  • 其他6月龄前推荐疫苗覆盖率两组均超过85%。

核心结论

  • 产前暴露于抗TNFα的儿童中疫苗接种常未按推荐推迟,但6月龄前接种BCG未报告相关严重不良事件。

研究设计与样本

  • 法国全国人群回顾性队列,数据来自法国健康保险数据库,纳入2013–2014年IBD母亲所生子女4741名。

主要发现

  • 670名(14.1%)产前暴露于抗TNFα,其中16.0%(n=107)联用硫嘌呤,19.3%(n=214)联用激素。
  • 暴露儿BCG接种率13.1%(88/670)低于未暴露儿19.2%(780/4071),P<.05。
  • 暴露儿BCG接种平均月龄4.3±3.9,晚于未暴露儿2.4±2.9,P<.001。
  • 暴露儿中88名接种BCG者73%(64/88)在6月龄前接种,首年无BCG相关严重不良事件。
  • 两组6月龄前其他推荐疫苗覆盖率均超过85%。

临床怎么用

  • 产前抗TNFα暴露儿接种BCG前应权衡现有安全性数据与指南推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Children born to mothers with IBD may be exposed to anti-TNFα agents antenatally. Current European guidelines recommend postponing live vaccines until after 6 months of life in this population. Data on the safety of live vaccines administration in the first year of life of these children are sparse with one reported fatality following bacillus Calmette-Guerin (BCG) administration. AIMS: To describe the use and safety of vaccines administered in children born to mothers with IBD and exposed antenatally to anti-TNFα agents METHODS: Data from children born to mothers with IBD between 2013 and 2014 were collected retrospectively from the French Health Insurance Database. Vaccines recommended before or at 1 year of age were considered. RESULTS: Among 4741 children, 670 (14.1%) were exposed to anti-TNFα agents antenatally, with concomitant thiopurines in 16.0% (n = 107) and steroids in 19.3% (n = 214). Among these 670 children, 315 (47%) were exposed up to delivery. Exposed children were less likely than non-exposed to receive BCG (88/670, 13.1% vs 780/4071, 19.2% respectively, P < .05) and received it later in life (months, mean ± SD, 4.3 ± 3.9 and 2.4 ± 2.9 respectively, P < .001). In exposed children, 64/88 (73%) received BCG vaccination before 6 months of age, but with no BCG-related severe adverse event observed during the first year. Uptake of other vaccines recommended before 6 months was above 85% in both groups. CONCLUSION: In children exposed antenatally to anti-TNFα agents, vaccinations are often not postponed in keeping with the recommendations, but no BCG-related severe adverse events were reported in children vaccinated before 6 months of life.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Luu M, Benzenine E, Barkun A, et al. Safety of first year vaccination in children born to mothers with inflammatory bowel disease and exposed in utero to anti-TNFα agents: a French nationwide population-based cohort. Aliment Pharmacol Ther. 2019. PMID: 31617226. doi:10.1111/apt.15504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。